Evolving Paradigms in Chronic Graft-Versus-Host Disease: From Global Immunosuppression to Precision Targeted and Cell-Based Therapies.

Yu Wang, Wanying Liu, Xiaobing Huang, Yi Xiao

Abstract readSystematic Review

In one paragraph

Synthesis in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yu WangDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095, Jiefang Road, Qiaokou District, Wuhan, Hubei, 430030, P.R. China.

Wanying LiuDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095, Jiefang Road, Qiaokou District, Wuhan, Hubei, 430030, P.R. China.

Xiaobing HuangDepartment of Hematology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, No. 32, West Section 2, First Ring Road, Chengdu City, Sichuan, P.R. China, 611072. huangxiaobing@med.uestc.edu.cn.

Yi XiaoDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095, Jiefang Road, Qiaokou District, Wuhan, Hubei, 430030, P.R. China. yixiao@tjh.tjmu.edu.cn.

Funding

National Natural Science Foundation of China No.81873444

6 · The paper itself

Abstract

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a well-established treatment for a range of medical conditions. However, the procedure carries with it a significant risk of chronic graft-versus-host disease (cGVHD), which can have a considerable impact on patients’ quality of life and clinical outcomes. In recent years, there has been a marked shift in treatment strategies for this condition, with greater emphasis being placed on novel targeted therapies and cell therapies that target specific pathways. This shift in approach signifies a more profound comprehension of the pathogenesis of the condition, particularly with respect to abnormal T/B cell activation, tissue fibrosis progression, and immune tolerance imbalance. This article systematically reviews the current treatment framework and latest advances in cGVHD, covering the evolution from first-line immunosuppression to diverse precision targeted drugs and cellular therapy strategies. The study methodically analyses their positioning in clinical practice and the challenges encountered, with the objective of providing theoretical support and practical guidance for refined, individualised clinical management of cGVHD.

Indexed as

Cell- and Tissue-Based TherapyGraft vs Host DiseaseImmunosuppression TherapyAge FactorsAnimalsBiological ProductsEnzyme InhibitorsHematopoietic Stem Cell TransplantationHumansImmunosuppressive AgentsSignal TransductionBiological ProductsEnzyme InhibitorsImmunosuppressive AgentsAnti-CSF-1R monoclonal antibodiesBTK inhibitorsCellular immunityChronic graft-versus-host diseaseJAK inhibitorsMesenchymal stem cellsROCK2 inhibitors

Identifiers

PMID42008224

DOI10.1007/s12015-026-11131-7

PMCPMC13241463

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.